Invesco Ltd. filed an amended Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 1,520,911 shares of Ligand Pharmaceuticals Inc common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Invesco Ltd. reported beneficial ownership of 1,520,911 shares of Ligand Pharmaceuticals Inc common stock.
  • Percent of class: The disclosed position represents 7.6% of the outstanding class of common stock, according to the filing.
  • Sole voting power: Invesco Ltd. reported sole voting power over 1,497,232 shares, with shared voting power of zero.
  • Sole dispositive power: The filing attributes sole dispositive power over 1,520,911 shares to Invesco Ltd., with shared dispositive power of zero.
  • Triggering event date: The date of the event requiring this filing was September 30, 2026.
  • Subsidiaries involved: The filing identifies Invesco Advisers, Inc., Invesco Asset Management Limited, and Invesco Capital Management LLC as the relevant subsidiaries through which the shares are held.

Invesco Ltd. Discloses Amended 13G Position in Ligand Pharmaceuticals

Invesco Ltd., organized in Bermuda and headquartered at 1331 Spring Street NW, Suite 2500, Atlanta, GA 30309, filed Amendment No. 1 to its Schedule 13G regarding its holdings in Ligand Pharmaceuticals Inc (NASDAQ:LGND). According to the filing, Invesco Ltd. acted in its capacity as a parent holding company to its investment advisers and may be deemed to beneficially own 1,520,911 shares held of record by clients of Invesco Ltd. The filing classifies Invesco Ltd. as a holding company (HC) and investment adviser (IA).

The filing reports that sole voting power covers 1,497,232 shares, while sole dispositive power covers the full 1,520,911 shares. Shared voting and shared dispositive power are each reported as zero. Three subsidiaries are identified in connection with the position: Invesco Advisers, Inc., Invesco Asset Management Limited, and Invesco Capital Management LLC. The filing states that "no one person has greater than 5% economic ownership in the securities listed above" and that the relevant clients of Invesco Ltd. retain the right to receive dividends and proceeds from the sale of the securities.

The filing was signed by Robert R. Leveille, Global Head of Compliance for Invesco Ltd., on November 9, 2026. The certification included in the filing states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Invesco Ltd. filed an amended Schedule 13G disclosing beneficial ownership of 1,520,911 shares, or 7.6%, of Ligand Pharmaceuticals Inc common stock (CUSIP 53220K504) as of September 30, 2026, held through three named investment adviser subsidiaries.